Cargando...
Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A
Development of inhibitors to factor VIII (FVIII) occurs in approximately 30% of severe hemophilia A (HA) patients. These patients are treated with bypassing agents (activated prothrombin complex concentrate [aPCC] and recombinant activated FVII-rFVIIa). Recently, a bispecific FIX/FIXa- and FX/FXa-di...
Guardado en:
| Publicado en: | TH Open |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Georg Thieme Verlag KG
2020
|
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7373667/ https://ncbi.nlm.nih.gov/pubmed/32704613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0040-1710032 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|